RESUMEN
Hepatitis B virus (HBV) molecular profiles were determined for 44 patients who were infected with human immunodeficiency virus (HIV) type 1 and had antibodies to the hepatitis B core antigen (anti-HBc), with and without other HBV serological markers. In this population, 70 percent of the patients were under lamivudine treatment as a component of antiretroviral therapy. HBV DNA was detected in 14 (32 percent) patients. Eight out of 12 (67 percent) HBsAg positive samples, 3/10 (30 percent) anti-HBc only samples, and 3/22 (14 percent) anti-HBs positive samples were HBV DNA positive. HBV DNA loads, measured by real time polymerase chain reaction, were much higher in the HBsAg positive patients (mean, 2.5 Î 10(9) copies/ml) than in the negative ones (HBV occult infection; mean, 2.7 Î 10(5) copies/ml). Nine out of the 14 HBV DNA positive patients were under lamivudine treatment. Lamivudine resistant mutations in the polymerase gene were detected in only three patients, all of them belonging to the subgroup of five HBsAg positive, HBV DNA positive patients. A low mean HBV load (2.7 Î 10(5) copies/ml) and an absence of lamivudine resistant mutations were observed among the cases of HBV occult infection.